The Human Genome Editing Race: Loosening Regulatory Standards for Commercial Advantage?
- PMID: 30017092
- DOI: 10.1016/j.tibtech.2018.06.005
The Human Genome Editing Race: Loosening Regulatory Standards for Commercial Advantage?
Abstract
Medicinal products based on genome editing must undergo rigorous preclinical testing and are subject to regulatory oversight for proper risk assessment prior to first evaluation in humans. We give a European perspective on the regulatory expectations to translate genome editing to the clinic to ensure their timely progress to market.
Keywords: CRISPR; clinical trials; commercialization; ethics; genome editing; regulation.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources